Ashley B. Anderson
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Ashley B. Anderson has a total of 96 co-authors. Here are the top co-authors by number of shared publications:
- Benjamin Kyle Potter
Department of Surgery, Uniformed Services University of Health Sciences, Bethesda, MD, USA
11 shared publications - Jonathan A. Forsberg
Orthopaedic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA
6 shared publications Benjamin K. Potter
John P. Murtha Cancer Center Walter Reed National Military Medical Center Bethesda Maryland USA
5 shared publications- Jonathan F. Dickens
Department of Orthopaedic Surgery, Duke University Medical Center, Durham, North Carolina
5 shared publications - Julio A. Rivera
School of Life Sciences Arizona State University Tempe Arizona USA
5 shared publications - Jason M. Souza
From the Department of Plastic and Reconstructive Surgery, The Ohio State University
4 shared publications
Latest Publications
- 9 April 2026
- Published by Wolters Kluwer Health in Journal of Orthopaedic Trauma
- Vol. 40 (8) , 440-445
Do amputation characteristics predict outcomes measures and infections after osseointegration surgery?
Objective: To determine which patient characteristics are associated with patient-reported outcomes and infection outcomes after transfemoral osseointegration surgery. Methods: Design: Single-center retrospective study. Setting: Walter Reed National Military Medical Center, Bethesda, MD. Patient Selection Criteria: Patients who underwent unilateral or bilateral transfemoral osseointegration surgery and completed 2-year follow-up. Outcome Measures and Comparisons: Baseline patient characteristics (age at primary amputation, time living with limb loss, residual femur length, age at osseointegration surgery, and limb-loss–adjusted body mass index [BMI]) were evaluated as predictors of change in patient-reported outcomes from baseline to 2-year follow-up (Q-TFA domains, PROMIS domains, and patient-reported prosthesis use) and of infection outcomes (any infection and number of infections), using generalized linear models with AIC-guided backward elimination and adjustment for amputation laterality (unilateral vs bilateral). Results: There were 54 patients included (37 unilateral and 17 bilateral) who completed 2-year follow-up. The unilateral cohort had a mean age of 41.1 years (range, 24–72) and was predominantly male (33 males, 4 females), whereas the bilateral cohort had a mean age of 33.6 years (range, 26–41) and consisted entirely of male patients. Adjusted BMI best predicted changes in Q-TFA Global (R 2 = 0.06, F(1,48) = 3.8, p = 0.05) and Problem scores (R 2 = 0.07, F(1,48) = 4.7, p = 0.03), as well as PROMIS Pain Interference (R 2 = 0.25, F(1,50) = 17.8, p < 0.001) and Pain Behavior scores (R 2 = 0.26, F(1,50) = 18.7, p < 0.001) between baseline and 2-year follow-up. Adjusted BMI also best predicted changes in Q-TFA Prosthetic Use, PROMIS Physical Function, and prosthesis use time. Adjusted BMI was the strongest predictor of the number of infections. Conclusion: Among unilateral and bilateral transfemoral amputees undergoing osseointegration surgery with 2-year follow-up, lower adjusted BMI was associated with improved patient-reported outcomes and fewer infection events. Differences between unilateral and bilateral amputees suggest amputation laterality may modify postoperative outcomes. Level of Evidence: Therapeutic Level III
- 9 April 2026
- Published by Wolters Kluwer Health in Journal of Orthopaedic Trauma
- Vol. 40 (8) , 440-445
Do amputation characteristics predict outcomes measures and infections after osseointegration surgery?
Objective: To determine which patient characteristics are associated with patient-reported outcomes and infection outcomes after transfemoral osseointegration surgery. Methods: Design: Single-center retrospective study. Setting: Walter Reed National Military Medical Center, Bethesda, MD. Patient Selection Criteria: Patients who underwent unilateral or bilateral transfemoral osseointegration surgery and completed 2-year follow-up. Outcome Measures and Comparisons: Baseline patient characteristics (age at primary amputation, time living with limb loss, residual femur length, age at osseointegration surgery, and limb-loss–adjusted body mass index [BMI]) were evaluated as predictors of change in patient-reported outcomes from baseline to 2-year follow-up (Q-TFA domains, PROMIS domains, and patient-reported prosthesis use) and of infection outcomes (any infection and number of infections), using generalized linear models with AIC-guided backward elimination and adjustment for amputation laterality (unilateral vs bilateral). Results: There were 54 patients included (37 unilateral and 17 bilateral) who completed 2-year follow-up. The unilateral cohort had a mean age of 41.1 years (range, 24–72) and was predominantly male (33 males, 4 females), whereas the bilateral cohort had a mean age of 33.6 years (range, 26–41) and consisted entirely of male patients. Adjusted BMI best predicted changes in Q-TFA Global (R 2 = 0.06, F(1,48) = 3.8, p = 0.05) and Problem scores (R 2 = 0.07, F(1,48) = 4.7, p = 0.03), as well as PROMIS Pain Interference (R 2 = 0.25, F(1,50) = 17.8, p < 0.001) and Pain Behavior scores (R 2 = 0.26, F(1,50) = 18.7, p < 0.001) between baseline and 2-year follow-up. Adjusted BMI also best predicted changes in Q-TFA Prosthetic Use, PROMIS Physical Function, and prosthesis use time. Adjusted BMI was the strongest predictor of the number of infections. Conclusion: Among unilateral and bilateral transfemoral amputees undergoing osseointegration surgery with 2-year follow-up, lower adjusted BMI was associated with improved patient-reported outcomes and fewer infection events. Differences between unilateral and bilateral amputees suggest amputation laterality may modify postoperative outcomes. Level of Evidence: Therapeutic Level III
- 3 March 2026
- Published by Wolters Kluwer Health in Clinical Orthopaedics and Related Research
- Vol. 484 (7) , 1385-1394
What Are the Patient-reported Outcomes After Elective Transtibial Amputation? A Comparison of CRPS, Neuropathic Pain, and Other Conditions That Lead to Late Amputation After Limb Salvage
Background: In the United States, approximately 2.3 million people live with limb loss, of whom about 91% have undergone lower extremity amputation. Despite these numbers, relatively few studies have evaluated outcomes after elective transtibial amputation. In particular, we do not know whether the outcomes after amputation for intractable neurogenic pain such as complex regional pain syndrome (CRPS) are comparable to outcomes after late amputations (6 weeks or more after limb salvage) performed for other reasons such as recurrent infection, soft tissue problems, recalcitrant nonunion, poor function, and chronic nonneurogenic pain. Questions/purposes: (1) Did patients who underwent late amputation for CRPS or neuropathic pain have inferior Patient-Reported Outcomes Measurement Information System (PROMIS) scores at follow-up compared with patients who had nonneurogenic elective amputation? (2) Did patients who underwent late amputation for CRPS or neuropathic pain have more pain, use more pain medication, or wear prosthetics less often than patients who have undergone nonneurogenic elective amputation? (3) Were patients who underwent late amputation for CRPS or neuropathic pain more likely to be revised to a higher level of amputation or express decision regret than patients undergoing nonneurogenic elective amputation? Methods: This retrospective comparative study examined 70% (50 of 71) of patients who underwent elective (that is, scheduled, nonurgent) transtibial amputation between July 2006 and September 2019 at least 6 weeks after lower extremity trauma (median [range] 2 years [6 weeks to 15 years]). Most patients were men (94% [47 of 50]) and active duty service members who sustained combat-related trauma (74% [37 of 50]). Patients with CRPS (defined using the Budapest criteria diagnostic guidelines, which requires ongoing disproportionate pain plus signs in four categories: sensory, vasomotor, sudomotor/edema, and motor/trophic changes, n = 10) and other forms of neuropathic pain (n = 10) were compared with a control group of patients who had nonneurogenic elective amputation (n = 30). Demographic characteristics among cohorts were not different given the numbers available. The median (range) follow-up was 9 years (3 to 16) after amputation. The primary outcome was the PROMIS pain interference score. Secondary outcomes included other PROMIS metrics, VAS pain, and patient-reported medication and prosthetic use as well as revision to a higher level of amputation and decision regret. Results: With the numbers available, we found no difference in PROMIS pain interference scores for patients with transtibial amputations performed for neurogenic pain compared with other causes of late amputation (median [range] 57 [45 to 64] versus 56 [39 to 72]; p = 0.81). There were likewise no differences with the numbers available in PROMIS physical function, mobility, life satisfaction, and severity of substance use. Amputations performed for neurogenic pain resulted in more pain reduction than late amputations for other causes (median ΔVAS -5 [-9 to -1] versus median Δ VAS -3 [-8 to 7]; p = 0.02). Both groups reported a reduction in opioid use (100% reduction in median frequency of opioid administrations for both groups; p < 0.001). Prosthetic use was not different with the numbers available among all cohorts. No patients in the CRPS plus neuropathic pain cohort were revised to a higher level of amputation compared with 2 patients in the nonneurogenic elective amputation cohort. No patients expressed definitive decision regret. Conclusion: Patients undergoing elective transtibial amputations for intractable neurogenic pain experienced clinically meaningful improvement in pain. Our findings support the use of transtibial amputation for treatment-resistant neurogenic pain, and they provide reasonable, but generally favorable, expectations for patients considering this irreversible procedure that are generally comparable to outcomes from patients undergoing late amputations for other indications. Level of Evidence: Level III, therapeutic study.
- 3 March 2026
- Published by Wolters Kluwer Health in Clinical Orthopaedics and Related Research
- Vol. 484 (7) , 1385-1394
What Are the Patient-reported Outcomes After Elective Transtibial Amputation? A Comparison of CRPS, Neuropathic Pain, and Other Conditions That Lead to Late Amputation After Limb Salvage
Background: In the United States, approximately 2.3 million people live with limb loss, of whom about 91% have undergone lower extremity amputation. Despite these numbers, relatively few studies have evaluated outcomes after elective transtibial amputation. In particular, we do not know whether the outcomes after amputation for intractable neurogenic pain such as complex regional pain syndrome (CRPS) are comparable to outcomes after late amputations (6 weeks or more after limb salvage) performed for other reasons such as recurrent infection, soft tissue problems, recalcitrant nonunion, poor function, and chronic nonneurogenic pain. Questions/purposes: (1) Did patients who underwent late amputation for CRPS or neuropathic pain have inferior Patient-Reported Outcomes Measurement Information System (PROMIS) scores at follow-up compared with patients who had nonneurogenic elective amputation? (2) Did patients who underwent late amputation for CRPS or neuropathic pain have more pain, use more pain medication, or wear prosthetics less often than patients who have undergone nonneurogenic elective amputation? (3) Were patients who underwent late amputation for CRPS or neuropathic pain more likely to be revised to a higher level of amputation or express decision regret than patients undergoing nonneurogenic elective amputation? Methods: This retrospective comparative study examined 70% (50 of 71) of patients who underwent elective (that is, scheduled, nonurgent) transtibial amputation between July 2006 and September 2019 at least 6 weeks after lower extremity trauma (median [range] 2 years [6 weeks to 15 years]). Most patients were men (94% [47 of 50]) and active duty service members who sustained combat-related trauma (74% [37 of 50]). Patients with CRPS (defined using the Budapest criteria diagnostic guidelines, which requires ongoing disproportionate pain plus signs in four categories: sensory, vasomotor, sudomotor/edema, and motor/trophic changes, n = 10) and other forms of neuropathic pain (n = 10) were compared with a control group of patients who had nonneurogenic elective amputation (n = 30). Demographic characteristics among cohorts were not different given the numbers available. The median (range) follow-up was 9 years (3 to 16) after amputation. The primary outcome was the PROMIS pain interference score. Secondary outcomes included other PROMIS metrics, VAS pain, and patient-reported medication and prosthetic use as well as revision to a higher level of amputation and decision regret. Results: With the numbers available, we found no difference in PROMIS pain interference scores for patients with transtibial amputations performed for neurogenic pain compared with other causes of late amputation (median [range] 57 [45 to 64] versus 56 [39 to 72]; p = 0.81). There were likewise no differences with the numbers available in PROMIS physical function, mobility, life satisfaction, and severity of substance use. Amputations performed for neurogenic pain resulted in more pain reduction than late amputations for other causes (median ΔVAS -5 [-9 to -1] versus median Δ VAS -3 [-8 to 7]; p = 0.02). Both groups reported a reduction in opioid use (100% reduction in median frequency of opioid administrations for both groups; p < 0.001). Prosthetic use was not different with the numbers available among all cohorts. No patients in the CRPS plus neuropathic pain cohort were revised to a higher level of amputation compared with 2 patients in the nonneurogenic elective amputation cohort. No patients expressed definitive decision regret. Conclusion: Patients undergoing elective transtibial amputations for intractable neurogenic pain experienced clinically meaningful improvement in pain. Our findings support the use of transtibial amputation for treatment-resistant neurogenic pain, and they provide reasonable, but generally favorable, expectations for patients considering this irreversible procedure that are generally comparable to outcomes from patients undergoing late amputations for other indications. Level of Evidence: Level III, therapeutic study.
- Open Access
A Comprehensive Review of Bone Remodeling After Trauma and Operative Treatment in Orthopedic Surgery
Bone remodeling is a dynamic process involving bone resorption and formation that is regulated on a cellular level and impacted by mechanical stress. A variety of Orthopedic surgery treatment strategies can affect bone remodeling, which can in turn may have long-term impacts on skeletal stress tolerance and function. This review provides a comprehensive overview of bone remodeling involved in Orthopedic surgery. Materials related to bone remodeling principles across Orthopedic surgery domains were selected and compiled using databases including PubMed, MEDLINE, AccessMedicine, and CINAHL; case studies were not included. Relevant literature was summarized for a general review of bone remodeling and as it relates to treatment principles in trauma, arthroplasty, and amputation with the aim of providing a relevant, comprehensive review. Overall, the purpose of this review is to provide an overview of bone remodeling principles that are implicated in various techniques within Orthopedic surgery.
Open AccessA Comprehensive Review of Bone Remodeling After Trauma and Operative Treatment in Orthopedic Surgery
Bone remodeling is a dynamic process involving bone resorption and formation that is regulated on a cellular level and impacted by mechanical stress. A variety of Orthopedic surgery treatment strategies can affect bone remodeling, which can in turn may have long-term impacts on skeletal stress tolerance and function. This review provides a comprehensive overview of bone remodeling involved in Orthopedic surgery. Materials related to bone remodeling principles across Orthopedic surgery domains were selected and compiled using databases including PubMed, MEDLINE, AccessMedicine, and CINAHL; case studies were not included. Relevant literature was summarized for a general review of bone remodeling and as it relates to treatment principles in trauma, arthroplasty, and amputation with the aim of providing a relevant, comprehensive review. Overall, the purpose of this review is to provide an overview of bone remodeling principles that are implicated in various techniques within Orthopedic surgery.
- Open Access
- 22 September 2025
- Published by Wiley in Cancer Medicine
- Vol. 14 (18) , e71201
Do Race, Insurance Status, and Income Factors Impact Pathologic Fracture Presentation and Management?
Introduction: Metastatic bone disease (MBD) and pathologic fractures (PF) can impact quality of life, functionality, and survival. Understanding the management of PF and access to care and treatment in the U.S. healthcare system can improve patient outcomes, directly impacting treatment eligibility and overall survival. We ask: (1) Do race, income, and insurance status differ between prophylactic stabilization of impending and acute fixation of overt PF, respectively? (2) Are race, income, and insurance status associated with complications in patients with metastatic bone disease? (3) Are race, income, and insurance associated with length of stay and insurance type in patients with MBD? Methods: The NIS HCUP database was queried from 2016 to 2020 for pathological fractures. We then identified patients with associated cancer ICD‐10 diagnostic codes for the hospitalization (breast, prostate, renal, lung, thyroid, bone, and other). General linear models (GLMs) were used to answer each clinical question. We conducted a post hoc analysis of the other malignancies associated with osseous metastasis and performed the same studies as above. Results: We found 2050 prophylactically stabilized impending and 4181 acute fractures. There were no differences among races, income, or insurance status and the prevalence of impending versus acute fractures. We found that Black patients were more likely to have complications, while Hispanic patients were the least likely, compared to other races. Black patients had higher hospital costs, while both Black and Hispanic patients had more extended hospitalizations and were more likely to have Medicaid or no insurance compared to other races. Our post hoc analyses found that the rate of impending and acute fractures differed among race, income, and insurance status, depending on the metastatic cause. Conclusions: We identified healthcare disparities in patients with impending and overt PF due to MBD despite minimal to no differences in patient comorbidities, fracture management, or hospitalization complications.
- 22 September 2025
- Published by Wiley in Cancer Medicine
- Vol. 14 (18) , e71201
Open AccessDo Race, Insurance Status, and Income Factors Impact Pathologic Fracture Presentation and Management?
Introduction: Metastatic bone disease (MBD) and pathologic fractures (PF) can impact quality of life, functionality, and survival. Understanding the management of PF and access to care and treatment in the U.S. healthcare system can improve patient outcomes, directly impacting treatment eligibility and overall survival. We ask: (1) Do race, income, and insurance status differ between prophylactic stabilization of impending and acute fixation of overt PF, respectively? (2) Are race, income, and insurance status associated with complications in patients with metastatic bone disease? (3) Are race, income, and insurance associated with length of stay and insurance type in patients with MBD? Methods: The NIS HCUP database was queried from 2016 to 2020 for pathological fractures. We then identified patients with associated cancer ICD‐10 diagnostic codes for the hospitalization (breast, prostate, renal, lung, thyroid, bone, and other). General linear models (GLMs) were used to answer each clinical question. We conducted a post hoc analysis of the other malignancies associated with osseous metastasis and performed the same studies as above. Results: We found 2050 prophylactically stabilized impending and 4181 acute fractures. There were no differences among races, income, or insurance status and the prevalence of impending versus acute fractures. We found that Black patients were more likely to have complications, while Hispanic patients were the least likely, compared to other races. Black patients had higher hospital costs, while both Black and Hispanic patients had more extended hospitalizations and were more likely to have Medicaid or no insurance compared to other races. Our post hoc analyses found that the rate of impending and acute fractures differed among race, income, and insurance status, depending on the metastatic cause. Conclusions: We identified healthcare disparities in patients with impending and overt PF due to MBD despite minimal to no differences in patient comorbidities, fracture management, or hospitalization complications.
- 7 May 2025
- Published by Oxford University Press (OUP) in Military Medicine
Estimating the 5-Year Publication Potential for Grant Awardees: Analysis of the Peer Reviewed Orthopaedic Research Program
Introduction: Research-funding agencies are sometimes criticized for their ineffective review of grant proposals and for prioritizing competition for grants over project outcomes. Deficiencies in the review process for grants may limit the diversity of a program’s applicant pool and restrict opportunities for publication. Our study asked what features of Peer Reviewed Orthopaedic Research Program (PRORP) grants and grant recipients were associated with successful grant outcomes, with success defined as publication of results within 5 years of receipt of funding. Materials and Methods: Using data from all PRORP grants from 2009 to 2017, we built machine-learned predictive models to estimate publication within 5 years. Features included in the analysis were principal investigator characteristics (sex, degree, and institution type) and grant characteristics (research grant mechanism, primary and secondary research topics, and amount awarded). We evaluated model performance using calibration plots and then determined the models’ discriminatory ability by estimating the area under the receiver operator curve and c-statistic. Then we used Brier scores to obtain an overall assessment of each model’s accuracy. We ultimately selected 1 model for administrative use based on its performance measures. Results: The Bayesian generalized linear model performed best (area under the curve, 0.82 [95% CI, 0.68-0.95]; Brier score, 0.17 [95% CI, 0.10-0.23]) and therefore was selected. It showed administrative utility in decision curve analysis. Awardee features most strongly associated with publication were previous award winner (no), principal investigator specialty (anesthesiology), sex (male), degree (PhD), and institution type (university). Grant features most strongly associated with publication were primary topic (stem cell therapy and chemoprevention), secondary topic (biologics), research type (in vitro study and animal validation), award mechanism (translational research), award amount > median amount ($598,000), and award years 2010-2011. Conclusions: This model can aid the PRORP in identifying awardees who will successfully publish, and funding agencies and policymakers likewise can use it to apportion grants in a manner that promotes diversity across the applicant pool.
- 7 May 2025
- Published by Oxford University Press (OUP) in Military Medicine
Estimating the 5-Year Publication Potential for Grant Awardees: Analysis of the Peer Reviewed Orthopaedic Research Program
Introduction: Research-funding agencies are sometimes criticized for their ineffective review of grant proposals and for prioritizing competition for grants over project outcomes. Deficiencies in the review process for grants may limit the diversity of a program’s applicant pool and restrict opportunities for publication. Our study asked what features of Peer Reviewed Orthopaedic Research Program (PRORP) grants and grant recipients were associated with successful grant outcomes, with success defined as publication of results within 5 years of receipt of funding. Materials and Methods: Using data from all PRORP grants from 2009 to 2017, we built machine-learned predictive models to estimate publication within 5 years. Features included in the analysis were principal investigator characteristics (sex, degree, and institution type) and grant characteristics (research grant mechanism, primary and secondary research topics, and amount awarded). We evaluated model performance using calibration plots and then determined the models’ discriminatory ability by estimating the area under the receiver operator curve and c-statistic. Then we used Brier scores to obtain an overall assessment of each model’s accuracy. We ultimately selected 1 model for administrative use based on its performance measures. Results: The Bayesian generalized linear model performed best (area under the curve, 0.82 [95% CI, 0.68-0.95]; Brier score, 0.17 [95% CI, 0.10-0.23]) and therefore was selected. It showed administrative utility in decision curve analysis. Awardee features most strongly associated with publication were previous award winner (no), principal investigator specialty (anesthesiology), sex (male), degree (PhD), and institution type (university). Grant features most strongly associated with publication were primary topic (stem cell therapy and chemoprevention), secondary topic (biologics), research type (in vitro study and animal validation), award mechanism (translational research), award amount > median amount ($598,000), and award years 2010-2011. Conclusions: This model can aid the PRORP in identifying awardees who will successfully publish, and funding agencies and policymakers likewise can use it to apportion grants in a manner that promotes diversity across the applicant pool.
- 28 April 2025
- Published by BMJ in BMJ Case Reports
- Vol. 18 (4) , e263745
Utilising intraoperative hand-held cryoneurolysis for enhanced post-thoracotomy pain control
Post-thoracotomy pain (PTP) is a challenging complication following thoracic surgery, often leading to chronic, debilitating symptoms. However, little is known about the potential of intraoperative cryoneurolysis (IC) as a solution for managing PTP. This retrospective case series reports the application of IC in three patients undergoing thoracic surgery for chest wall tumors. Under direct visualisation of the intercostal nerves, temporary inhibition of nerve signalling was achieved without disrupting the surrounding tissue using a handheld device. All three patients experienced decreased pain and reduced reliance on opioids during the 6 week postoperative period. These outcomes highlight the potential of IC to improve post-thoracotomy pain management.
- 28 April 2025
- Published by BMJ in BMJ Case Reports
- Vol. 18 (4) , e263745
Utilising intraoperative hand-held cryoneurolysis for enhanced post-thoracotomy pain control
Post-thoracotomy pain (PTP) is a challenging complication following thoracic surgery, often leading to chronic, debilitating symptoms. However, little is known about the potential of intraoperative cryoneurolysis (IC) as a solution for managing PTP. This retrospective case series reports the application of IC in three patients undergoing thoracic surgery for chest wall tumors. Under direct visualisation of the intercostal nerves, temporary inhibition of nerve signalling was achieved without disrupting the surrounding tissue using a handheld device. All three patients experienced decreased pain and reduced reliance on opioids during the 6 week postoperative period. These outcomes highlight the potential of IC to improve post-thoracotomy pain management.
- Top Cited Papers
- 31 January 2025
- Published by Wolters Kluwer Health in Clinical Orthopaedics and Related Research
- Vol. 483 (3) , 513-523
What Functional Outcomes Can Be Expected With Osseointegrated Prostheses in Transfemoral Amputations?
Background: Individuals who have undergone transfemoral amputation often have difficulty donning and utilizing a conventional socket prosthesis. Osseointegrated prostheses may alleviate certain issues, potentially resulting in better outcomes, but few prospective studies have either evaluated these outcomes or quantified the purported benefits. Questions/purposes: (1) Did patient-reported outcome measures improve between baseline and 2-year follow-up among those who underwent osseointegration surgery after transfemoral amputation? (2) What was the frequency and severity of early complications related to the osseointegration procedures? (3) What was the minimum clinically important difference (MCID) in a global patient-reported outcome measure in this patient population? Methods: Between October 2017 and October 2023, we recruited 41 participants to undergo transfemoral osseointegration surgery treated with the Osseointegrated Prostheses for the Rehabilitation of Amputees implant system for patients who had trouble utilizing traditional, socket-based prostheses. Of those, 5% (2 of 41) did not undergo surgery, 2% (1 of 41) were lost to follow-up, and 2% (1 of 41) died before the final 2-year follow-up, leaving 90% (37 of 41) for analysis in this prospective, observational trial. Participants were asked to complete the validated Questionnaire for Persons with a Transfemoral Amputation (Q-TFA) and the Patient-Reported Outcomes Measurement Information System (PROMIS) questionnaire before surgery as well as 3, 6, 12, and 24 months after the two-stage procedure. Thirty-seven participants (three women and 34 men; mean ± SD age 38 ± 10 years) reached the 24-month follow-up visit, and four patients were withdrawn. We tabulated the frequency and types of surgical complications that patients experienced and calculated the anchored-based MCID for the Q-TFA global score (0 to 100 maximum). The Q-TFA’s global score is generated based on answers to three questions: “How would you summarize your level of function with your current prosthesis?”, “How would you summarize the problems you experience with your current prosthesis?”, and “How would you summarize your overall situation as an amputee?” Using the sum of the numerical scores for the three questions, we found the difference between the baseline and the final follow-up for the participants. Then, we took the first quartile of the difference to represent the median change in the lower 25% of the data and used this value as our MCID. Results: Scores in the study group improved in nearly all domains of the Q-TFA and PROMIS, including those related to prosthetic use, prosthetic mobility, and physical function (all p < 0.05). Patients developed superficial infections in 29% (15 of 51) of implanted limbs, all of which were treated successfully with antibiotics alone; 7 patients developed deep infections, only 1 of which involved the bone and implant. The anchor-based MCID in the Q-TFA global score was calculated as 17 of 100 for this study population. Conclusion: Functional patient-reported outcomes improved in multiple domains among our patient cohort who underwent osseointegration surgery after transfemoral amputation, demonstrating the promise of this technology for patients with unsatisfactory function using conventional, socket-based prostheses. Infections and other complications were lower than in prior studies of osseointegration following limb loss. The novel MCID that we report can be used to determine whether patients have clinically important improvement in future osseointegration surgery studies comparing results between different implants, surgical techniques, and patient populations. Level of Evidence: Level II, therapeutic study.
- 31 January 2025
- Published by Wolters Kluwer Health in Clinical Orthopaedics and Related Research
- Vol. 483 (3) , 513-523
Top Cited PapersWhat Functional Outcomes Can Be Expected With Osseointegrated Prostheses in Transfemoral Amputations?
Background: Individuals who have undergone transfemoral amputation often have difficulty donning and utilizing a conventional socket prosthesis. Osseointegrated prostheses may alleviate certain issues, potentially resulting in better outcomes, but few prospective studies have either evaluated these outcomes or quantified the purported benefits. Questions/purposes: (1) Did patient-reported outcome measures improve between baseline and 2-year follow-up among those who underwent osseointegration surgery after transfemoral amputation? (2) What was the frequency and severity of early complications related to the osseointegration procedures? (3) What was the minimum clinically important difference (MCID) in a global patient-reported outcome measure in this patient population? Methods: Between October 2017 and October 2023, we recruited 41 participants to undergo transfemoral osseointegration surgery treated with the Osseointegrated Prostheses for the Rehabilitation of Amputees implant system for patients who had trouble utilizing traditional, socket-based prostheses. Of those, 5% (2 of 41) did not undergo surgery, 2% (1 of 41) were lost to follow-up, and 2% (1 of 41) died before the final 2-year follow-up, leaving 90% (37 of 41) for analysis in this prospective, observational trial. Participants were asked to complete the validated Questionnaire for Persons with a Transfemoral Amputation (Q-TFA) and the Patient-Reported Outcomes Measurement Information System (PROMIS) questionnaire before surgery as well as 3, 6, 12, and 24 months after the two-stage procedure. Thirty-seven participants (three women and 34 men; mean ± SD age 38 ± 10 years) reached the 24-month follow-up visit, and four patients were withdrawn. We tabulated the frequency and types of surgical complications that patients experienced and calculated the anchored-based MCID for the Q-TFA global score (0 to 100 maximum). The Q-TFA’s global score is generated based on answers to three questions: “How would you summarize your level of function with your current prosthesis?”, “How would you summarize the problems you experience with your current prosthesis?”, and “How would you summarize your overall situation as an amputee?” Using the sum of the numerical scores for the three questions, we found the difference between the baseline and the final follow-up for the participants. Then, we took the first quartile of the difference to represent the median change in the lower 25% of the data and used this value as our MCID. Results: Scores in the study group improved in nearly all domains of the Q-TFA and PROMIS, including those related to prosthetic use, prosthetic mobility, and physical function (all p < 0.05). Patients developed superficial infections in 29% (15 of 51) of implanted limbs, all of which were treated successfully with antibiotics alone; 7 patients developed deep infections, only 1 of which involved the bone and implant. The anchor-based MCID in the Q-TFA global score was calculated as 17 of 100 for this study population. Conclusion: Functional patient-reported outcomes improved in multiple domains among our patient cohort who underwent osseointegration surgery after transfemoral amputation, demonstrating the promise of this technology for patients with unsatisfactory function using conventional, socket-based prostheses. Infections and other complications were lower than in prior studies of osseointegration following limb loss. The novel MCID that we report can be used to determine whether patients have clinically important improvement in future osseointegration surgery studies comparing results between different implants, surgical techniques, and patient populations. Level of Evidence: Level II, therapeutic study.
Incidence rates of soft tissue sarcoma among U.S. military servicemen: Comparison with the rates in the general U.S. population
Background: Soft tissue sarcoma (STS) is one of the most frequently diagnosed cancers among men younger than age 30 years and a leading cause of cancer death in men younger than age 40 years. The military may be more exposed to STS risk factors and have generally better health and health care access than the general population, which may relate to lower cancer risk and/or early detection. This study compared STS incidence between servicemen and men in the general U.S. population.Methods: Data were from the Department of Defense’s Automated Central Tumor Registry (ACTUR) and the National Cancer Institute’s Surveillance, Epidemiology, and End Results (SEER) program. Subjects were active‐duty servicemen in ACTUR and men in SEER aged 18–59 years diagnosed with STS from 1990 to 2013. Age‐adjusted rates, incidence rate ratios (IRR), and 95% CIs were calculated.Results: STS incidence rates were lower in ACTUR than SEER overall (IRR = 0.86 [0.78‐0.93]), for 18‐ to 39‐year‐old men (IRR = 0.78 [0.70‐0.86]), by race (White: IRR = 0.85 [0.77‐0.95]; Black: IRR = 0.77 [0.63‐0.94]), for sites other than skin/connective/soft tissue (IRR = 0.49 [0.37‐0.63]), other specified histologies (IRR = 0.84 [0.71‐0.98]), and unspecified histology (IRR = 0.57 [0.38‐0.82]). Rates were lower in ACTUR for regional (IRR = 0.37 [0.28‐0.47]) and distant metastases (IRR = 0.58 [0.43‐0.76]), even when race and age stratified. However, rates were higher in ACTUR for 40‐ to 59‐year‐old men (IRR = 1.25 [1.04‐1.48]) and localized tumors (IRR = 1.16 [1.04‐1.29]).Conclusion: Lower STS rates among servicemen may relate to better health and early detection and treatment of STS‐associated conditions within the military health system, which provides universal care. Higher rates among 40‐ to 59‐year‐old servicemen may result from greater cumulative military‐related exposures.
Incidence rates of soft tissue sarcoma among U.S. military servicemen: Comparison with the rates in the general U.S. population
Background: Soft tissue sarcoma (STS) is one of the most frequently diagnosed cancers among men younger than age 30 years and a leading cause of cancer death in men younger than age 40 years. The military may be more exposed to STS risk factors and have generally better health and health care access than the general population, which may relate to lower cancer risk and/or early detection. This study compared STS incidence between servicemen and men in the general U.S. population.Methods: Data were from the Department of Defense’s Automated Central Tumor Registry (ACTUR) and the National Cancer Institute’s Surveillance, Epidemiology, and End Results (SEER) program. Subjects were active‐duty servicemen in ACTUR and men in SEER aged 18–59 years diagnosed with STS from 1990 to 2013. Age‐adjusted rates, incidence rate ratios (IRR), and 95% CIs were calculated.Results: STS incidence rates were lower in ACTUR than SEER overall (IRR = 0.86 [0.78‐0.93]), for 18‐ to 39‐year‐old men (IRR = 0.78 [0.70‐0.86]), by race (White: IRR = 0.85 [0.77‐0.95]; Black: IRR = 0.77 [0.63‐0.94]), for sites other than skin/connective/soft tissue (IRR = 0.49 [0.37‐0.63]), other specified histologies (IRR = 0.84 [0.71‐0.98]), and unspecified histology (IRR = 0.57 [0.38‐0.82]). Rates were lower in ACTUR for regional (IRR = 0.37 [0.28‐0.47]) and distant metastases (IRR = 0.58 [0.43‐0.76]), even when race and age stratified. However, rates were higher in ACTUR for 40‐ to 59‐year‐old men (IRR = 1.25 [1.04‐1.48]) and localized tumors (IRR = 1.16 [1.04‐1.29]).Conclusion: Lower STS rates among servicemen may relate to better health and early detection and treatment of STS‐associated conditions within the military health system, which provides universal care. Higher rates among 40‐ to 59‐year‐old servicemen may result from greater cumulative military‐related exposures.
- 30 October 2024
- Published by Wolters Kluwer Health in Clinical Orthopaedics and Related Research
- Vol. 483 (4) , 740-745
Do Fellowship-educated Military Orthopaedic Oncologists Who Practice in Military Settings Treat a Sufficient Volume of Patients to Maintain Their Oncologic Expertise?
Background: Fellowship-trained orthopaedic oncologists in the US military provide routine clinical care and also must maintain readiness to provide combat casualty care. However, low oncologic procedure volume may hinder the ability of these surgeons to maintain relevant surgical expertise. Other low-volume specialties within the Military Health System (MHS) have established partnerships with neighboring civilian centers to increase procedure volume, but the need for similar partnerships for orthopaedic oncologists has not been examined. The purpose of this study was to characterize the practice patterns of US military fellowship–trained orthopaedic oncologists. Questions/purposes: We asked the following questions: (1) What are the diagnoses treated by US military fellowship–trained orthopaedic oncologists? (2) What are the procedures performed by US military fellowship–trained orthopaedic oncologists? Methods: We queried the Military Data Repository, a centralized repository for healthcare data for all healthcare beneficiaries (active duty, dependents, and retirees) within the Defense Health Agency using the MHS’s Management and Reporting Tool for all international common procedure taxonomy (CPT) codes and ICD-9 and ICD-10 codes associated with National Provider Identifier (NPI) numbers of active duty, military fellowship–trained orthopaedic oncologists. Fellowship-trained orthopaedic oncologists were identified by military specialty leaders. Then, we identified all procedures performed by the orthopaedic oncologist based on NPI numbers for fiscal years 2013 to 2022. We stratified the CPT codes by top orthopaedic procedure categories (such as amputation [performed for oncologic and nononcologic reasons], fracture, arthroplasty, oncologic) based on associated ICD codes. These were then tabulated by the most common diagnoses treated. Results: Thirteen percent (796 of 5996) of the diagnoses were oncologic, of which 45% (357 of 796) were malignant. Forty-four percent (158 of 357) of the malignancies were primary and 56% (199 of 357) were secondary; this translates to an average of 2 patients with primary and 2.5 patients with secondary malignancies treated per surgeon per year. During the study period, nine orthopaedic oncologists performed 5996 orthopaedic procedures, or 74 procedures per surgeon per year. Twenty-one percent (1252 of 5996) of the procedures were oncologic; the remaining procedures included 897 arthroplasties, 502 fracture-related, 275 amputations for a nononcologic indication, 204 infections, 142 arthroscopic, and 2724 other procedures. Conclusion: Although military orthopaedic oncologists possess expert skills that are directly translatable to combat casualty care and operational readiness, within MHS hospitals they treat relatively few patients with oncologic diagnoses, and less than one-half of those involve malignancies. Clinical Relevance: Despite postgraduation procedure volume raining stable over the last decade, it is unknown how many new patient visits for oncologic diagnoses and how many corresponding tumor procedures are necessary to maintain competence or build confidence after musculoskeletal oncology fellowship training. It is important to note that there are no military orthopaedic oncology fellowships, and all active duty orthopaedic oncologists undergo training at civilian institutions. Military-civilian partnerships with high-volume cancer centers may enable military orthopaedic oncologists to work at civilian cancer centers to increase their oncologic volume to ensure sustainment of operationally relevant knowledge, skills, and abilities and improve patient care and outcomes.
- 30 October 2024
- Published by Wolters Kluwer Health in Clinical Orthopaedics and Related Research
- Vol. 483 (4) , 740-745
Do Fellowship-educated Military Orthopaedic Oncologists Who Practice in Military Settings Treat a Sufficient Volume of Patients to Maintain Their Oncologic Expertise?
Background: Fellowship-trained orthopaedic oncologists in the US military provide routine clinical care and also must maintain readiness to provide combat casualty care. However, low oncologic procedure volume may hinder the ability of these surgeons to maintain relevant surgical expertise. Other low-volume specialties within the Military Health System (MHS) have established partnerships with neighboring civilian centers to increase procedure volume, but the need for similar partnerships for orthopaedic oncologists has not been examined. The purpose of this study was to characterize the practice patterns of US military fellowship–trained orthopaedic oncologists. Questions/purposes: We asked the following questions: (1) What are the diagnoses treated by US military fellowship–trained orthopaedic oncologists? (2) What are the procedures performed by US military fellowship–trained orthopaedic oncologists? Methods: We queried the Military Data Repository, a centralized repository for healthcare data for all healthcare beneficiaries (active duty, dependents, and retirees) within the Defense Health Agency using the MHS’s Management and Reporting Tool for all international common procedure taxonomy (CPT) codes and ICD-9 and ICD-10 codes associated with National Provider Identifier (NPI) numbers of active duty, military fellowship–trained orthopaedic oncologists. Fellowship-trained orthopaedic oncologists were identified by military specialty leaders. Then, we identified all procedures performed by the orthopaedic oncologist based on NPI numbers for fiscal years 2013 to 2022. We stratified the CPT codes by top orthopaedic procedure categories (such as amputation [performed for oncologic and nononcologic reasons], fracture, arthroplasty, oncologic) based on associated ICD codes. These were then tabulated by the most common diagnoses treated. Results: Thirteen percent (796 of 5996) of the diagnoses were oncologic, of which 45% (357 of 796) were malignant. Forty-four percent (158 of 357) of the malignancies were primary and 56% (199 of 357) were secondary; this translates to an average of 2 patients with primary and 2.5 patients with secondary malignancies treated per surgeon per year. During the study period, nine orthopaedic oncologists performed 5996 orthopaedic procedures, or 74 procedures per surgeon per year. Twenty-one percent (1252 of 5996) of the procedures were oncologic; the remaining procedures included 897 arthroplasties, 502 fracture-related, 275 amputations for a nononcologic indication, 204 infections, 142 arthroscopic, and 2724 other procedures. Conclusion: Although military orthopaedic oncologists possess expert skills that are directly translatable to combat casualty care and operational readiness, within MHS hospitals they treat relatively few patients with oncologic diagnoses, and less than one-half of those involve malignancies. Clinical Relevance: Despite postgraduation procedure volume raining stable over the last decade, it is unknown how many new patient visits for oncologic diagnoses and how many corresponding tumor procedures are necessary to maintain competence or build confidence after musculoskeletal oncology fellowship training. It is important to note that there are no military orthopaedic oncology fellowships, and all active duty orthopaedic oncologists undergo training at civilian institutions. Military-civilian partnerships with high-volume cancer centers may enable military orthopaedic oncologists to work at civilian cancer centers to increase their oncologic volume to ensure sustainment of operationally relevant knowledge, skills, and abilities and improve patient care and outcomes.
- 1 July 2024
- Published by Wolters Kluwer Health in JBJS Reviews
- Vol. 12 (7)
Team Approach: Osseointegration Amputation Surgery
Update: This article was updated on August 7, 2024 because of a previous error. On page 1, the last sentence of the abstract that had read “We hope this model will service as an implant-agnostic guide to others seeking to development an osseointegration center of excellence.” should have read “We hope this model will serve as an implant-agnostic guide to others seeking to develop an osseointegration center of excellence.” now reads “We hope this model will serve as an implant-agnostic guide to others seeking to develop an osseointegration center of excellence.”. An erratum has been published: JBJS Rev. 2024;12(8):e24.00048ER. » The purpose of this article was to review the multidisciplinary, team-based approach necessary for the optimal management of patients with limb loss undergoing osseointegration surgery. » In this study, we describe the interdisciplinary process of screening, counseling, and surgical and rehabilitation considerations with an emphasis on principles rather than specific implants or techniques. » Integrated perioperative management and long-term surveillance are crucial to ensure the best possible outcomes. » We hope this model will serve as an implant-agnostic guide to others seeking to develop an osseointegration center of excellence.
- 1 July 2024
- Published by Wolters Kluwer Health in JBJS Reviews
- Vol. 12 (7)
Team Approach: Osseointegration Amputation Surgery
Update: This article was updated on August 7, 2024 because of a previous error. On page 1, the last sentence of the abstract that had read “We hope this model will service as an implant-agnostic guide to others seeking to development an osseointegration center of excellence.” should have read “We hope this model will serve as an implant-agnostic guide to others seeking to develop an osseointegration center of excellence.” now reads “We hope this model will serve as an implant-agnostic guide to others seeking to develop an osseointegration center of excellence.”. An erratum has been published: JBJS Rev. 2024;12(8):e24.00048ER. » The purpose of this article was to review the multidisciplinary, team-based approach necessary for the optimal management of patients with limb loss undergoing osseointegration surgery. » In this study, we describe the interdisciplinary process of screening, counseling, and surgical and rehabilitation considerations with an emphasis on principles rather than specific implants or techniques. » Integrated perioperative management and long-term surveillance are crucial to ensure the best possible outcomes. » We hope this model will serve as an implant-agnostic guide to others seeking to develop an osseointegration center of excellence.